Spero Therapeutics Inc (NAS:SPRO)
$ 1.03 0.0861 (9.12%) Market Cap: 56.15 Mil Enterprise Value: -20.21 Mil PE Ratio: 12.88 PB Ratio: 0.85 GF Score: 39/100

Q4 2020 Spero Therapeutics Inc Earnings Call Transcript

Mar 11, 2021 / 09:30PM GMT
Release Date Price: $17.92 (+6.86%)
Operator

Greetings, and welcome to Spero Therapeutics Fourth Quarter and Full Year 2020 Financial Results Call. (Operator Instructions).

As a reminder, this conference is being recorded. It is now my pleasure to introduce your host for today's call, Sharon Klahre. Thank you. You may begin.

Sharon Klahre
Spero Therapeutics, Inc. - VP of IR & Strategic Finance

Great. Thank you, operator, and thank you all for participating in today's conference call. Earlier today, Spero Therapeutics released financial results and provided a pipeline update for the fourth quarter and full year 2020. If you have not yet seen the press release, it's available on the Investor page of the Spero Therapeutics website.

Before I begin, I'd like to remind you that some of the information contained in the press release and on this conference call contain forward-looking statements based on our current expectations. Including statements about the initiation, timing and submission to the FDA of the NDA for tebipenem HBr and the potential approval of tebipenem HBr by the FDA,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot